Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24554
Full metadata record
DC FieldValueLanguage
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorPetris, C.en
dc.contributor.authorBairaktari, E.en
dc.contributor.authorKarabina, S. A.en
dc.contributor.authorTzallas, C.en
dc.contributor.authorTselepis, A.en
dc.contributor.authorSiamopoulos, K. C.en
dc.date.accessioned2015-11-24T19:41:53Z-
dc.date.available2015-11-24T19:41:53Z-
dc.identifier.issn0950-9240-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24554-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAntihypertensive Agents/*therapeutic useen
dc.subjectBlood Pressure/drug effectsen
dc.subjectCopper/pharmacologyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectHypertension/*blood/*drug therapyen
dc.subjectImidazoles/*therapeutic useen
dc.subjectLipids/*blooden
dc.subjectLipoproteins, LDL/*blood/metabolismen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectOxidation-Reduction/drug effectsen
dc.subjectTreatment Failureen
dc.titleThe effect of moxonidine on plasma lipid profile and on LDL subclass distributionen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10578224-
heal.identifier.secondaryhttp://www.nature.com/jhh/journal/v13/n11/pdf/1000835a.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1999-
heal.abstractMoxonidine is a new antihypertensive agent whose mechanism of action appears to involve specific stimulation of imidazoline receptors resulting in an inhibition of the activity of the central and peripheral sympathetic nervous system. The drug seems to behave neutrally with respect to plasma lipid parameters. However, there are no data on the effects of moxonidine on the low-density lipoprotein (LDL) subclass pattern or on the LDL oxidation susceptibility, both of which are known to play a prominent role in the pathogenesis of atherosclerosis. Thus, we undertook the present study to examine the influence of moxonidine on the LDL subspecies profile and their susceptibility to copper-induced oxidative modification in 20 hypertensive patients (11 men, 9 women) aged 38-61 years. Moxonidine administered at a dose of 0.4 mg daily for 8 weeks produced a significant decrease in both systolic and diastolic blood pressure (from 147 +/- 10 to 131 +/- 11 mm Hg, P < 0.001, and from 98 +/- 4.5 to 86 +/- 5 mm Hg, P < 0.001, respectively). No significant change in plasma lipid profile was observed after moxonidine administration. Additionally, no change in the susceptibility of LDL subclasses to copper-induced oxidative modification was noticed. Finally, drug therapy was not followed by any change in either LDL phenotype or in mass and composition of the three LDL subfractions. We conclude, that unlike other antihypertensive drugs, such as beta-blockers which may predispose to expression of a relatively atherogenic lipoprotein subclass pattern, moxonidine does not affect either plasma lipid parameters or lipoprotein composition.en
heal.journalNameJ Hum Hypertensen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Elisaf-1999-The effect of moxoni.pdf123.78 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons